Ezgi Pinar

Ezgi Pinar

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
EPEveline van Poelgeest
Eveline van Poelgeest
LPLuca Paoletti
Luca Paoletti
SÖSerdar Özkök
Serdar Özkök
EPEzgi Pinar
Ezgi Pinar
Gülistan BahatGülistan Bahat
Gülistan Bahat
NVNathalie van der Velde
Nathalie van der Velde
In this systematic review, we report on the effects of diuretic deprescribing compared to continued diuretic use. We included clinical studies reporting on outcomes such as mortality, heart failure recurrence, tolerability and feasibility. We assessed risk of bias and certainty of the evidence using the GRADE framework. We included 25 publications from 22 primary studies (15 randomized controlled trials; 7 nonrandomized studies). The mean number of participants in the deprescribing groups was 35, and median/mean age 64 years. In patients with heart failure, there was no clear evidence that diuretic deprescribing was associated with increased mortality compared to diuretic continuation (low certainty evidence). The risk of cardiovascular composite outcomes associated with diuretic deprescribing was inconsistent (studies showing lower risk for diuretic deprescribing, or comparable risk with diuretic continuation; very low certainty evidence). The effect on heart failure recurrence after diuretic deprescribing in patients with diuretics for heart failure, and of hypertension in patients with diuretics for hypertension was inconsistent across the included studies (low certainty evidence). In patients with diuretics for hypertension, diuretic deprescribing was well tolerated (moderate certainty evidence), while in patients with diuretics for heart failure, deprescribing diuretics can result in complaints of peripheral oedema (very low certainty evidence). The overall risk of bias was generally high. In summary, this systematic review suggests that diuretic discontinuation could be a safe and feasible treatment option for carefully selected patients. However, there isa lack of high‐quality evidence on its feasibility, safety and tolerability of diuretic deprescribing, warranting further research.

19 December 2025 in Clinical Nutrition
Verified
Journal Article
Closed access
Gülistan BahatGülistan Bahat
Gülistan Bahat
EPEzgi Pinar
Ezgi Pinar
OAOsman Abbasoglu
Osman Abbasoglu
MKMehmet Akif Karan
Mehmet Akif Karan
SOSavas Ozturk
Savas Ozturk
YOYusuf Ozogul
Yusuf Ozogul

1 December 2022 in Turkish Journal of Hematology
Verified
Journal Article
Open access
MOMurat Ozbalak
Murat Ozbalak
MMMetban Mastanzade
Metban Mastanzade
DÖDilek Özden Özlük
Dilek Özden Özlük
TTtarık onur Tiryaki
tarık onur Tiryaki
SESimge Erdem
Simge Erdem
SBSevgi Kalayoglu Besısık
Sevgi Kalayoglu Besısık
Objective: Redditux (R) (RED), as a biosimilar rituximab, was approved in Turkey for all indications of the original Mabthera (R) (MAB) in March 2018. The aim of our study was to evaluate the efficacy and safety of RED in de novo diffuse large B-cell lymphoma. Materials and Methods: Fifty-one patients received RED combined with the CHOP regimen. The median follow-up was 31 months. The historical control group included 219 patients treated with the MAB-CHOP regimen and the median follow-up time was 38 months. We compared the response rates and survival outcomes of these RED-CHOP and MAB-CHOP cohorts. Results: In the RED cohort, the overall response rate (ORR) at the end of the treatment protocol was 86%, with 37 (72.5%) cases of complete response (CR) and 7 (13.5%) cases of partial response (PR). In the historical MAB cohort, the ORR was 84%, with CR and PR rates of 82% and 2%, respectively. The 24-month progression-free survival (PFS) rates were 73.76% (95% confidence interval [CI]: 0.59-0.84) and 85.2% (95% CI: 0.79-0.90) for the RED and MAB cohorts, respectively (p=0.0106). The 24-month overall survival rates were 78.4% (95% CI: 0.64-0.87) and 81.4% (95% CI: 0.75-0.86) for the RED and MAB cohorts, respectively (p=0.7461). For patients with high revised International Prognostic Index scores, 24-month PFS was 45.5% (95% CI: 0.17-0.71) and 63% (95% CI: 0.37-0.80) for the RED and MAB cohorts, respectively (p=0.0711). In the RED cohort, central nervous system (CNS) relapse was significantly increased compared to the MAB cohort (10% vs. 1.83%, p=0.004). Among the RED cohort, bone involvement at the time of diagnosis was a risk factor for CNS relapse (p=0.028). Thirteen patients died in follow-up. There were no serious adverse events causing the cessation of the drugs. Conclusion: RED has an ORR similar to that of MAB. However, PFS rates were worse in the RED cohort. Additionally, CNS relapse ratio was a major concern for our RED cohort. Large prospective controlled studies and real-life data with longer follow-up are needed to document the non-inferiority of RED compared to MAB.

9 December 2025 in Nutrition
Verified
Journal Article
Closed access
Gülistan BahatGülistan Bahat
Gülistan Bahat
TETuğba Erdoğan
Tuğba Erdoğan
EPEzgi Pinar
Ezgi Pinar
SÖSerdar Özkök
Serdar Özkök
MKMehmet AKİF Karan
Mehmet AKİF Karan
OAOsman Abbasoğlu
Osman Abbasoğlu

1 September 2021 in İstanbul Kanuni Sultan Süleyman Tıp dergisi
Verified
Journal Article
Closed access
MOMurat Ozbalak
Murat Ozbalak
MMMetban Mastanzade
Metban Mastanzade
ÖÖÖzden Özlük
Özden Özlük
TTtarık onur Tiryaki
tarık onur Tiryaki
EPEzgi Pinar
Ezgi Pinar
SBSevgi Kalayoglu Besısık
Sevgi Kalayoglu Besısık